Fungal keratitis
================

Definition:
-----------

Fungal keratitis (keratomycosis) is a fungal infection of the cornea. It primarily affects the corneal epithelium and stroma, although the endothelium and anterior chamber of the eye may get involved in more severe disease.

Incidence:
----------

Fungal keratitis is primarily seen in tropical climates and is rare in temperate areas. Its incidence is between 6%--20% of all microbial keratitis cases depending on the geographic location.[@b1-opth-5-275],[@b2-opth-5-275] Traditionally, it is considered a disease of rural areas and is frequently caused by trauma with vegetative material. However, the major risk factor in developed countries is contact lens use at this time.[@b3-opth-5-275] Its incidence has been reported to be increasing due to widespread use of contact lenses, especially bandage contact lenses, and topical steroid usage.[@b3-opth-5-275],[@b4-opth-5-275] While tropical climates show a preponderance of filamentous fungi, temperate climates show higher percentages of yeast infections.[@b1-opth-5-275],[@b5-opth-5-275],[@b6-opth-5-275]

Economics:
----------

Although no studies evaluating the economic implications of fungal keratitis are available, this is primarily a disease of young, working adults and is becoming more common. These facts, combined with the need for prolonged, intensive treatment and relatively poor visual outcomes, suggest that the adverse economic implications are significant.

Level of evidence:
------------------

Systematic reviews and randomized controlled trials (RCTs). Cohort and observational studies were also reviewed for additional data.

Search sources:
---------------

PubMed, Cochrane Library.

Outcomes:
---------

The main outcomes are: Resolution of the infectious process as rapidly as possibleGood visual outcomeDecrease in adverse outcomes such as the need for a therapeutic keratoplasty or loss of the eye.

Consumer summary:
-----------------

Fungal keratitis is an infection of the cornea by fungal organisms. It was traditionally thought to be caused by trauma with vegetative matter but contact lenses are now the most common etiology in developed countries. It is a difficult infection to treat and adverse outcomes such as the need for a corneal transplant or even eye removal are much more common compared to bacterial infections. Evidence suggests that this is because the current therapies are not very effective. Prolonged and aggressive therapy with antifungal medication and repeated debridement is necessary to treat this infection.[@b7-opth-5-275]

The evidence
============

  -------------------- ---
  Systematic reviews   3
  RCTs                 7
  Others               2
  -------------------- ---

There were three systematic reviews that evaluated the medical therapy of fungal keratitis. The Cochrane review[@b8-opth-5-275] in 2008 concluded that there was no evidence that the current available and investigational antifungal agents were effective. The review identified the need for large multicenter randomized trials. However, none of the studies they evaluated used either Amphotericin B or Voriconazole. The Hariprasad et al review[@b9-opth-5-275] evaluated over 40 laboratory studies and clinical case reports of treatment with voriconazole and concluded that it may be used safely and effectively against a broad range of fungal pathogens. In 2000, the O'Day and Head review[@b10-opth-5-275] concluded that although there had been progress in the treatment and outcomes of fungal keratitis, it was painfully slow. This was partly due to the almost total absence of interest in the problem by the pharmaceutical industry.

[Table 1](#t1-opth-5-275){ref-type="table"} shows the various RCTs that compared various antifungal medications to each other in terms of clinical outcomes. However, there was no specific medication that was shown to be superior to the others. Only three studies evaluated the visual outcomes and adverse outcomes between medication and are shown in [Table 2](#t2-opth-5-275){ref-type="table"}. In addition, there were two laboratory studies; one comparing antifungal medications for aspergillus in rabbits; and candida (isolates from 41 countries) by disk diffusion shown in [Table 3](#t3-opth-5-275){ref-type="table"}.

Conclusion
----------

As the studies indicate, there is no one good broad spectrum anti-fungal medication that is effective in all cases of fungal keratitis. The initial therapy should be based on the organism suspected. While Natamycin is the only commercially available medication, it has a limited therapeutic spectrum. Voriconazole or Amphotericin B may be better first line drugs in unknown cases as they have broader efficacy. Other medications do not offer any improvement over these drugs and should be reserved for therapeutic failures.

The practice
============

Potential pitfalls
------------------

Fungal organisms can penetrate through the corneal stroma without perforation of the cornea resulting in an infectious hypopyon or endothelial plaque. The problem is that the majority of antifungal medications have very poor penetration especially in the face of an intact epithelium. Unlike bacterial keratitis, the corneal epithelium overlying a stromal fungal infection can heal despite the presence of active infection once treatment is initiated and should not, by itself, be used as a guide to successful therapy.

Management
----------

Fungal keratitis should be suspected in cases of keratitis that do not respond to antibacterial agents especially in cases of vegetative trauma or extended wear contact lens usage. These cases should be scraped and sent for KOH or Gomorimethenamine silver stains as well as culture on Saboraud agar.

Assessment
----------

Feathery borders, ring infiltrate, endothelial plaque, fibrinoid aqueous, and satellite lesions should raise the suspicion of fungal keratitis ([Figure 1](#f1-opth-5-275){ref-type="fig"}). Endothelial plaques or an anterior chamber reaction usually indicate a more severe infection with penetration of fungal elements into the anterior chamber ([Figure 2](#f2-opth-5-275){ref-type="fig"}). Response to therapy is usually indicated by blunting of the feathery edges, re-epithelialization, or reduction in the anterior chamber reaction.

Treatment
---------

The only commercially available antifungal drug in the United States is Natamycin (also called Pimaricin) available as a 5% suspension. In other parts of the world where keratomycosis is seen much more frequently such as India, additional antifungal agents such as Fluconazole and Miconazole are available. However, various other drugs can be compounded into eye drops (by compounding pharmacies) and are effective. The most commonly used drugs are Voriconazole (1%),[@b7-opth-5-275],[@b11-opth-5-275] Amphotericin B (0.15%), Fluconazole, and Miconazole. Antiseptics such as Chlorhexidine 0.2% and Povidone iodine (5%) have also been advocated as cheap and easily available alternatives but are not as effective.[@b12-opth-5-275] Systemic antifungal medications have been advocated as adjunctive therapy in severe cases, especially ulcers with anterior chamber reaction but there have been no controlled studies showing a clear benefit of adding systemic antifungals.[@b13-opth-5-275],[@b14-opth-5-275]

Therapy should be aggressive and most authors advocate dual therapy to avoid the risk of resistance. Typically, the topical antifungals are given every hour initially. The duration of treatment is from 3--4 weeks on average. If efficacy is not noted within a week or there is worsening, consideration should be given to changing the medication to another class or asking the laboratory to run sensitivities on the cultured fungus.

If the infection continues to worsen or there is worsening anterior chamber reaction, surgical management may be indicated. This includes therapeutic keratoplasty and, in severe cases, enucleation may be necessary.

Indications for specialist referral
-----------------------------------

Small, superficial, peripheral ulcers can be managed in the community with a combination of frequent antifungal agents and epithelial debridement every three days. Large, deep, or central ulcers with an endothelial plaque, a hypopyon or fibrinoid aqueous should preferably be referred to a cornea specialist within a day. Paracentral ulcers may be managed in the community if smaller and without evidence of anterior chamber penetration. However, if no response is noted within a week, the physician should consider referring the patient to a specialist.

Further reading
---------------
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![Typical fungal ulcer with feathery borders.](opth-5-275f1){#f1-opth-5-275}

![Endothelial plaque, ring infiltrate, and hypopyon indicating a more advanced infection.](opth-5-275f2){#f2-opth-5-275}

###### 

RCTs comparing the clinical response of different antifungal medications

  **RCT**                           **Intervention**                                                                                          **Number of patients**   **Outcome criteria**                      **Outcomes**
  --------------------------------- --------------------------------------------------------------------------------------------------------- ------------------------ ----------------------------------------- --------------------------------------------------------------------------
  Mohan 1988[@b15-opth-5-275]       Topical Silver sulphadiazine vs Miconazole 1%                                                             40                       Clinical response by healing of ulcer     Silver sulphadiazine superior to miconazole
  Rahman 1998[@b16-opth-5-275]      Topical chlorhexidine 0.2% vs Natamycin 2.5%                                                              70                       Response at day 5 and healing by day 21   Chlorhexidine superior at both time points especially with severe ulcers
  Prajna 2003[@b17-opth-5-275]      Topical econazole 2% vs Topical Natamycin 5%                                                              112                      Clinical response by healing of ulcer     No difference
  Kalavathy 2005[@b18-opth-5-275]   Topical Itraconazole 1% vs Topical Natamycin 5%                                                           100                      Clinical response by healing of ulcer     No difference overall but Natamycin superior in Fusarium
  Mahdy 2010[@b19-opth-5-275]       Topical Amphotericin B 0.05% + subconjunctival injection Fluconazole 0.2% vs Topical Amphotericin 0.05%   48                       Clinical response by healing of ulcer     Combination therapy superior to monotherapy
  Prajna 2010[@b20-opth-5-275]      Topical Voriconazole 1% vs Topical Natamycin 5%                                                           120                      Time to re-epithelialization              No difference
  Arora 2010[@b21-opth-5-275]       Topical Voriconazole 1% vs Topical Natamycin 5%                                                           30                       Clinical response by healing of ulcer     No significant difference

###### 

RCTs evaluating the visual outcomes or adverse outcomes between antifungal medications

  **RCT**                        **Intervention**                                                                                **Number**   **Outcome criteria**                                               **Outcome**
  ------------------------------ ----------------------------------------------------------------------------------------------- ------------ ------------------------------------------------------------------ ---------------------------------------------------------------------------------------------------------------------------
  Mahdy 2010[@b19-opth-5-275]    Topical Amphotericin B 0.05% + subconjunctival Fluconazole 0.2% vs Topical Amphotericin 0.05%   48           Number of perforations and visual outcome                          Both therapies equivalent in both criteria
  Prajna 2010[@b20-opth-5-275]   Topical Voriconazole 1% vs Topical Natamycin 5%                                                 120          Visual acuity and number of perforations and corneal transplants   Visual acuity slightly superior in Voriconazole but not statistically significant. No difference in rate of complications
  Arora 2010[@b21-opth-5-275]    Topical Voriconazole 1% vs Topical Natamycin 5%                                                 30           Visual acuity                                                      No significant difference

###### 

Laboratory studies

  **Trial**                       **Intervention**                                           **Number**                         **Outcome criteria**            **Outcome**
  ------------------------------- ---------------------------------------------------------- ---------------------------------- ------------------------------- ------------------------------------------------------------------------------
  Panda 2003[@b12-opth-5-275]     Topical PHMB 0.02% vs povidone iodine 1% vs Natamycin 5%   24 Aspergillus rabbit infections   Healing time and perforations   Natamycin most effective, PHMB less effective, povidone-iodine not effective
  Pfaller 2010[@b22-opth-5-275]   Fluconazole (25 μg) vs voriconazole (1 μg)                 256,882 Candida isolates           80% growth inhibition           Voriconazole slightly superior but resistant organisms common to both
